Rite Aid Corporation February Same-Store Sales Up 1.5%
Rite Aidannounced today that same-store sales last month overall were up 1.5%. Front-end same-store sales decreased 1.8% while pharmacy same-store sales rose 3.1%. Total sales rose from $2.46 billion in the comparable period last year to $2.515 billion this year for the five-week period ended March 1, representing an increase of 2.4%.
Rite Aid said 0.5 percentage points of its front-end sales drop was attributable to the reduction in sales of over-the counter flu products. The company highlighted that its pharmacy same-store sales were up 3.1% for the period, even after accounting for a 1.4-percentage-point negative impact from the introduction of generic products. In total, prescription sales represented 69.1% of the total sales at Rite Aid.
On March 1, Rite Aid operated 4,587 stores, compared to 4,623 stores a year ago.
Yesterday, competitor Walgreen reported its comparable-store sales rose by 4.5% in February, while total sales were up 5% to $6.1 billion. It also noted the impact of a less virulent flu season.
For the quarter ended on March 1, Rite Aid saw total sales rise 2.2% to $6.6 billion -- a slightly slower pace than seen in February. However, same-store sales were up 2.1%, and the reduction in front-end sales was less visible, at a decline of 0.7%.
Rite Aid concluded its earnings update by noting that total sales for the 52-week period ended March 1 rose 0.5% to $25.4 billion, from $25.3 billion in the corresponding year-ago period.
The article Rite Aid Corporation February Same-Store Sales Up 1.5% originally appeared on Fool.com.
Patrick Morris has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
